Efficacy Of Anrotinib Maintenance Therapy After Concurrent Chemoradiotherapy In Unresectable Locally Advanced Non-small Cell Lung Cancer

Objective: To investigate the efficacy and safety of anrotinib single maintenance therapy after concurrent chemoradiotherapy for locally advanced unresectable non-small cell lung cancer(NSCLC).Methods: Choose 48 patients with locally advanced unresectable NSCLC who were admitted to Baotou Central Hospital from September 2019 to June 2021,Chest CT was reviewed one month after the end of concurrent radiotherapy and chemotherapy,and the patients with complete remission,partial remission or stable disease were evaluated and started oral anlotinib hydrochloride capsules maintenance therapy,12 mg each time,once a day,oral for two weeks,stop for one week,21 days as a treatment cycle.After that,vital signs,blood routine examination,urine routine examination,blood biochemistry,coagulation function,thyroid function,tumor markers and electrocardiogram were checked every two cycles.Chest CT was checked every three months to compare and evaluate the efficacy and observe the incidence of adverse reactions.Results: 1.As of the last follow-up date December 31,2021,41 of the 48 patients had reached the end point of Progress Free survival(PFS),with data maturity of85.4%,overall PFS of 6.4 to 24.8 months,and m PFS of 15.6 months(95% CI:13.78-17.43),the PFS rates at 12 months and 18 months were 72.2% and39.5%,respectively.2.Among the 48 patients,10 patients reached the OS endpoint,and the data maturity was 20.8%,not reaching the median OS.The OS rates at 12,18 and24 months were 93.1%,89.9% and 73.5%,respectively.3.The results of multivariate analysis showed that age,efficacy after concurrent chemoradiotherapy,CEA and CYFRA21-1 level were independent factors affecting PFS of patients.4.The security is good.The total incidence rate of adverse reactions was 75.0%(36/48)in 48 patients.There were no grade III/IV adverse events,mainly grade I/II adverse reactions:digestive tract reaction(18.8%),hypertension(29.2%),hand-foot syndrome(12.5%),abnormal liver function(4.2%),Fatigue/weakness(33.3%),urinary protein(6.3%),hemoptysis(0.0%),haemorrhage(0.0%),etc.Conclusions: Patients with unresectable locally advanced NSCLC were treated with arotinib maintenance therapy after concurrent radiotherapy and chemotherapy.In terms of median PFS of such patients,this scheme will significantly prolong compared with concurrent radiotherapy and chemotherapy alone.In terms of survival rate,the overall survival rate at 12 and 24 months is also higher than that of traditional radiotherapy and chemotherapy,which tends to prolong the overall survival(OS)of patients,and the tolerance and safety are good,It is one of the ideal schemes to improve the prognosis of patients.